A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL)

Trial Profile

A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Fludarabine (Primary) ; Treosulfan (Primary) ; Methotrexate; Tacrolimus
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 28 Jun 2010 Planned end date changed from Oct 2011 to Feb 2013 as reported by ClinicalTrials.gov.
    • 19 May 2010 Additional lead trial investigator identified as Boglarka Gyurkocza as reported by University of Washington Health Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top